Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Bone Biologics is a clinical-stage medical device company focused on bone regeneration in spinal fusion using its proprietary recombinant human protein, NELL-1. The lead product candidate, NB1 (NELL-1 combined with demineralized bone matrix), is being developed for lumbar spinal fusion. The company holds an exclusive worldwide license for the NELL-1 technology from the UCLA Technology Development Group.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,112,420) | $(8,948,731) |
| Net Loss Attributable to Common Stockholders | $(7,324,924) | $(8,948,731) |
| Operating Expenses | $4,219,161 | $9,428,303 |
| Research & Development (R&D) | $2,130,385 | $6,907,824 |
| General & Administrative (G&A) | $2,088,776 | $2,520,479 |
| Cash Used in Operating Activities | $(4,124,935) | $(9,555,904) |
| Cash Provided by Financing Activities | $4,423,497 | $5,044,161 |
| Cash and Cash Equivalents (Ending) | $3,325,131 | $3,026,569 |
| Accumulated Deficit | $(85,021,378) | $(80,908,958) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 55.3% to $4.2 million, driven primarily by a 69.2% reduction in R&D expenses ($4.8 million decrease). The 2023 period included significant one-time costs to produce NELL-1 protein for the initial clinical study.
- Legal Settlement: In 2023, the company recorded a $414,989 legal settlement expense (net of insurance). This item was absent in 2024 as the settlement was paid in early 2024.
- Warrant Liability: The change in fair value of warrant liability resulted in a gain of $51,081 in 2024, compared to a gain of $892,693 in 2023.
- Deemed Dividend: A non-cash deemed dividend of $3.2 million was recorded in 2024 related to a warrant inducement transaction, increasing the net loss attributable to common stockholders.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Milestones
- Clinical Progress: The company treated the first patients in 2024 in a multicenter, prospective, randomized pilot clinical study of NB1 in Australia. This triggered a $100,000 milestone payment to UCLA TDG.
- Capital Needs: Management estimates operating expenditures for the next twelve months at $4.7 million. Available cash is expected to fund operations through the fourth quarter of 2025.
- Financing: The company raised approximately $4.4 million in net proceeds during 2024 through public offerings, warrant exercises, and an "At The Market" (ATM) facility. Subsequent to year-end, an additional $347,549 was raised via the ATM facility.
Risks and Contingencies
- Going Concern: The company has incurred accumulated losses of approximately $85 million since inception. The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and the need for additional financing.
- Regulatory Approval: The lead product requires FDA Pre-Market Approval (PMA). There is no assurance that clinical trials will succeed or that regulatory approval will be obtained.
- Intellectual Property: The company relies on an exclusive license from UCLA TDG, which includes significant future milestone payments (up to $8 million in diligence fees and royalties) contingent on sales and approvals.
Key Facts for Investor Verification
- Liquidity Runway: Verify if the current cash balance of $3.3 million is sufficient to cover the estimated $4.7 million in operating expenditures for the next 12 months without immediate additional capital raises.
- Clinical Trial Status: Confirm the enrollment progress and safety data from the ongoing pilot clinical study in Australia, which is a prerequisite for a U.S. pivotal trial.
- Capital Raise Execution: Monitor the utilization of the ATM facility and the success of future equity or debt financing efforts to avoid dilution or operational scaling back.
- License Obligations: Review the specific terms of the UCLA TDG license agreement regarding future milestone payments and royalty rates upon commercialization.
- Warrant Inducement Impact: Understand the impact of the $3.2 million deemed dividend on the company's equity structure and future dilution potential.